Jade Homsi, M.D., is an Associate Professor in the Department of Internal Medicine at UT Southwestern Medical Center and a member of the Division of Hematology and Oncology. He is co-leader of the Melanoma Disease Oriented Team at UT Southwestern’s Harold C. Simmons Comprehensive Cancer Center. He is also the Clinical Chief of the Division of Hematology and Oncology.
It’s really meaningful for me to be part of a team that offers top-level cancer care right here in Dallas.
Originally from Damascus, Syria, Dr. Homsi earned his medical degree at Damascus University. He pursued a clinical research fellowship in medical oncology and palliative medicine at the Cleveland Clinic in Ohio. He then completed internal medicine residency training at Mercy Hospital in St. Louis, followed by advanced training through a fellowship in hematology and oncology at the University of South Florida/Moffitt Cancer Center in Tampa.
A Diplomate of the American Board of Internal Medicine, Dr. Homsi joined the UT Southwestern faculty in 2017.
Dr. Homsi's research interests include melanoma and sarcoma, with a focus on immunotherapy and early-phase clinical trials. He has authored or co-authored more than 40 articles based on his research. Dr. Homsi's clinical interests include melanoma and soft tissue and bone sarcomas.
At UT Southwestern, Dr. Homsi is a Leader on the Sarcoma and Melanoma oriented teams. He is Chair of the Division Gastrointestinal Oncology Recruitment Committee and Chair of the Department Recruitment and Retention Committee. He is a member of several committees, including the Department of Internal Medicine PIC Committee, the Assistant Professor Mentorship Committee, the Division of Hematology and Oncology Strategic Operations Committee, the Department of Internal Medicine Wellness Committee, and more.
Dr. Homsi is a member of the American Society of Clinical Oncology.
- Medical School
- Damascus University School of Medicine, Syria (1995)
- Mercy Hospital (2004), Internal Medicine
- University of South Florida/Moffitt Cancer Center (2007), Hematology Oncology
- Phase 1 Trials
- Skin Cancer
- A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma.
- Patel SP, Kim DW, Bassett RL, Cain S, Washington E, Hwu WJ, Kim KB, Papadopoulos NE, Homsi J, Hwu P, Bedikian AY Cancer Immunol. Immunother. 2017 Jun
- A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma.
- Hersh EM, Del Vecchio M, Brown MP, Kefford R, Loquai C, Testori A, Bhatia S, Gutzmer R, Conry R, Haydon A, Robert C, Ernst S, Homsi J, Grob JJ, Kendra K, Agarwala SS, Li M, Clawson A, Brachmann C, Karnoub M, Elias I, Renschler MF, Hauschild A Ann. Oncol. 2015 Nov 26 11 2267-74
- Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients.
- Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, Wu R, Lizee G, Mahoney S, Alvarado G, Glass M, Johnson VE, McMannis JD, Shpall E, Prieto V, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Patel S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Davies MA, Mansaray R, Fulbright OJ, Toth C, Ramachandran R, Wardell S, Gonzalez A, Hwu P Clin. Cancer Res. 2012 Dec 18 24 6758-70
- BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma.
- Kim J, Lazar AJ, Davies MA, Homsi J, Papadopoulos NE, Hwu WJ, Bedikian AY, Woodman SE, Patel SP, Hwu P, Kim KB J. Cutan. Pathol. 2012 Sep 39 9 821-5
- Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy.
- Joseph RW, Peddareddigari VR, Liu P, Miller PW, Overwijk WW, Bekele NB, Ross MI, Lee JE, Gershenwald JE, Lucci A, Prieto VG, McMannis JD, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Hwu P, Radvanyi LG Clin. Cancer Res. 2011 Jul 17 14 4882-91
- Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma.
- Homsi J, Bedikian AY, Papadopoulos NE, Kim KB, Hwu WJ, Mahoney SL, Hwu P Melanoma Res. 2010 Dec 20 6 507-10
- Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients.
- Homsi J, Bedikian AY, Kim KB, Papadopoulos NE, Hwu WJ, Mahoney SL, Hwu P Melanoma Res. 2009 Aug 19 4 238-42
- Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.
- Homsi J, Cubitt CL, Zhang S, Munster PN, Yu H, Sullivan DM, Jove R, Messina JL, Daud AI Melanoma Res. 2009 Jun 19 3 167-75
- Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies.
- Homsi J, Simon GR, Garrett CR, Springett G, De Conti R, Chiappori AA, Munster PN, Burton MK, Stromatt S, Allievi C, Angiuli P, Eisenfeld A, Sullivan DM, Daud AI Clin. Cancer Res. 2007 Oct 13 19 5855-61
- Melanoma of the anal canal: a case series.
- Homsi J, Garrett C Dis. Colon Rectum 2007 Jul 50 7 1004-10
Rethinking Phase I Trials: Going beyond toxicity in evaluating new agents. In ASCO Education Book
Homsi J (2007).
Honors & Awards
- Team Science Award
Melanoma Research Alliance (2011)
- K12 Mentored Clinical Scientist Award
National Institutes of Health (2006-2007)
- Merit Award
American Society of Clinical Oncology Annual Meeting (2006)
- Pain Merit Award
American Society of Clinical Oncology Annual Meeting (2001)
- American Society of Clinical Oncology (2004)